RELIVE is an international registry for patients with a relapsed or refractory hepatoblastoma or heoatocellular carcinoma.
Liver cancer is very rare in children (1% of all childhood cancers).
RELIVE was created in association with researchers from Australia, Canada, Europe, Japan, New Zealand and the USA within the framework of the CHIC (Children’s Hepatic International Collaboration) project. We aim to form the first international registry for all children relapsing from liver cancer in order to improve the survival of children suffering from this pathology.
Longterm outcome for patients with refractory or relapsed HB or HCC is clearly unsatisfactory. The international consortium currently conducting the PHITT trial plans to incorporate treatment guidelines and data acquisition in a prospective fashion for relapsed and refractory patients as part of a second generation protocol. To guide writing of this future proposal, this group first plans to broadly collect rertrospective data regarding recently used treatments for relapsed and refractory disease and the associated short- and longterm patient outcomes. The majority of candidate patients will have been treated at primary diagnosis within a clinical trial. However, the trials conducted by the major collaborative groups (SIOPEL, GPOH, JPLT, COG) did not collect the details of the treatment patients received for their relapsed or refractory disease. Anecdotal information is not sufficient; therefore, we propose to retrospectively collect all such cases in a central registry which will permit us to achieve a systematic overview and a statistical assessment of the various approaches used.